Non-Small Cell Lung Cancer (NSCLC) Therapeutics – A Global Market Overview

This global Non-Small Cell Lung Cancer Therapeutics report analyzes the market based on Cancer Type (Adenocarcinoma, Squamous cell carcinoma (SCC), Large cell carcinoma, Other Cancers), Therapy Type (Targeted Therapies, Immunotherapy, Chemotherapy, Radiation Therapy, Others), End-User (Hospitals, Specialty Clinics, Other End-Users) , and by geographic region (North America, Europe, Asia-Pacific, South America and Middle East & Africa for 2021-2030 period in terms of value in US$ million, projected from 2024 through 2030. The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics is estimated at US$27.7 billion in 2024 and is anticipated to record a CAGR of 10.3% during the 2024-2030 analysis period and stand at a projected US$50 billion by 2030.

本全球非小细胞肺癌治疗药物市场报告基于癌症类型（腺癌、鳞状细胞癌（SCC）、大细胞癌、其他癌症）、治疗类型（靶向治疗、免疫治疗、化学治疗、放射治疗、其他）、终端用户（医院、专科诊所、其他终端用户）以及地理区域（北美、欧洲、亚太地区、南美洲及中东非洲）对2021-2030年期间的市场进行分析，以百万美元计的价值，并从2024年预测至2030年。预计2024年全球非小细胞肺癌（NSCLC）治疗药物市场将达到277亿美元，在2024-2030年的分析期间预计实现10.3%的复合年增长率，并预计到2030年将达到500亿美元。